Surviving the current economic turbulence has added new challenges and complexity to an industry already weakened by anaemic R&D output, increased pricing pressures and shifting stakeholder expectations. As pharmaceutical leaders face critical strategic choices -- choices that have the potential to change everything about today’s “big pharma” business model -- there is an urgency to accelerate change.
Lessons from change: the life sciences industry
How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.
/$FILE/14L00209.JPG)